Physician profile
Gregory Coram
NPI 1548373384
$5,450.43
in general payments reported to CMS, 2019-2025
23 companies · $836 in 2025
The $836 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,000 · 2022: $1,106 · 2023: $1,518 · 2024: $989 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,891.88 | 2021-2025 | |
| Alkermes, INC. | $563.09 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $548.61 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $392.22 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $369.50 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $276.45 | 2021-2025 | Rexulti |
| Indivior INC. | $203.10 | 2021-2024 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $173.64 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $156.59 | 2022-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $127.80 | 2022-2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $105.08 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $104.64 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $89.10 | 2022-2024 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $83.80 | 2021-2022 | |
| Almatica Pharma LLC | $81.91 | 2023-2025 | Loreev Xr, Sertraline Hcl |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $78.57 | 2021-2023 | Fanapt, Hetlioz |
| Corium, LLC | $72.09 | 2023-2024 | Azstarys |
| Braeburn INC. | $44.31 | 2023-2025 | Brixadi |
| Noven Therapeutics, LLC | $27.59 | 2022 | |
| Neuronetics, INC. | $20.77 | 2023 | Neurostar Tms Therapy System |
| Neos Therapeutics, Lp | $14.49 | 2022 | |
| Adlon Therapeutics L.P. | $12.96 | 2021 | |
| Eisai INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Coram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.